François-Xavier Mahon, Mathieu Molimard. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh： See more » Antineoplastic Agents/administration & dosageAntineoplastic Agents/pharmacokineticsBenzamidesCytogenetic AnalysisDrug MonitoringFemaleFusion Proteins, bcr-abl/analysisHumansImatinib MesylateIn Situ Hybridization, FluorescenceLeukemia, Myelogenous, Chronic, BCR-ABL Positive/bloodLeukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosisLeukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapyLeukemia, Myeloid, Accelerated PhaseLeukemia, Myeloid, Chronic-PhaseMaleMiddle AgedPiperazines/administration & dosagePiperazines/pharmacokineticsPolymerase Chain ReactionPyrimidines/administration & dosagePyrimidines/pharmacokineticsRisk Assessment
Substances： See more » Antineoplastic AgentsBenzamidesPiperazinesPyrimidinesImatinib MesylateFusion Proteins, bcr-abl
Year: 2009 PMID： 19395027 DOI： 10.1016/j.leukres.2009.02.030
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156